Media Center

GLOBAL NEWS

PAGE:   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment

Holzkirchen, Germany, August 31, 2016

New data just published in a leading medical journal shows for the first time that the rate of treatment persistence for patients using the innovative Sandoz AirFluSal Forspiro respiratory inhaler is more than twice as high as for the reference product

FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases

Holzkirchen, Germany, August 30, 2016

Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) approved Erelzi (etanercept-szzs) for all indications included in the reference product label

Launch of novel on-demand news service Transplant TODAY from TTS 2016 transplant congress

Holzkirchen, August 09, 2016

Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access to latest news from the 26th International Congress of The Transplantation Society (TTS2016).

Novartis Second Quarter 2016 Results

Basel, July 19, 2016

Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects

Keep Data in Biosimilar Labeling Clear

Holzkirchen, July 15, 2016

In an op-ed published last week Carlos Sattler, MD, Vice President of Clinical Development and Medical Affairs, emphasized the need for a regulatory environment that creates a level playing field for biosimilars.

Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases

Holzkirchen, July 13, 2016

Sandoz, a Novartis division and leader in biosimilars, announced today that the US Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of its proposed biosimilar etanercept

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Holzkirchen, July 07, 2016

The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12

Dr. Harald Nusser speaks to This Week in Global Health

July 04, 2016

An interview with Dr. Harald Nusser on how Novartis Access is helping to increase access to medicines to treat non-communicable diseases (NCDs).

“Access Unplugged”: We have the opportunity – and the duty – to lead the global debate

June 29, 2016

Sandoz has a responsibility to drive access to medicines, which has always been central to our value proposition, and to help lead the public debate about the best ways of addressing global healthcare challenges.

Competing sustainably in biosimilars – more than just a numbers game

Holzkirchen, June 24, 2016

Following the Biosimilars Media Day in Schaftenau, Austria, Carol Lynch comments on what it will take to succeed in the global biosimilars market.

Sandoz announces plans for five major global biosimilar launches by 2020

Holzkirchen, June 20, 2016

Sandoz, a Novartis Division and the global leader in biosimilars, plans to launch five biosimilars of major oncology and immunology biologics across ...

New data demonstrates Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products

Holzkirchen, June 09, 2016

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies comparing its biosimilar etanercept and rituximab candidates with the originator products ...

Novartis Access - Read out from second stakeholder dialogue event during WHA

June 06, 2016

A LinkedIn commentary by Harald Nusser, Global Head of Novartis Access.

Sandoz’ biosimilar rituximab regulatory submission accepted by European Medicines Agency

Holzkirchen, May 24, 2016

Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche’s EU-licensed MabThera® (rituximab). Rituximab is a monoclonal antibody that is used ...

Ecuador earthquake recovery: Sandoz announces financial support and product donation

Holzkirchen, May 23, 2016

In the wake of the earthquake that devastated northwest Ecuador in April, Sandoz, a Novartis division, today announced that it will support the recovery effort with financial aid and a product donation.

Partnerships towards Universal Health Coverage (UHC)

Holzkirchen, May 20, 2016

A LinkedIn commentary by Harald Nusser, Global Head of Novartis Access.

A decade of progress – and still just beginning

Holzkirchen, May 11, 2016

Carol Lynch, Global Head of Biopharmaceuticals and Chair of the European Biosimilars Group, reflects on a decade of biosimilars.

Sandoz’s Carol Lynch, Global Head Biopharmaceuticals is recognized in a Top 100 list, as the eighth most influential individual in medicine making.

Holzkirchen, April 29, 2016

Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients

World Malaria Day

Holzkirchen, April 26, 2016

On World Malaria Day, Richard Francis, Division Head & CEO, Sandoz, and Member of the Novartis Executive Committee, reflects on Sandoz’ commitment to driving research, development and access to novel drugs to eliminate malaria.

Novartis Q1 Results 2016

Basel, April 21, 2016

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth.

Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit’s® nephrology indication

Holzkirchen, April 08, 2016

EC approval expands Sandoz biosimilar offering to the healthcare community

Novartis publishes updated 2015 segment financials reflecting new division structure

Basel, March 31, 2016

Novartis announced today that it has published updated 2015 quarterly and full year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the transfers had taken place from January 1, 2015.

New research highlights need for a competitive functioning biologics market to achieve full potential of biosimilars

Holzkirchen, March 29, 2016

New research published today in a report from the IMS Institute for Healthcare Informatics

EGA becomes Medicines for Europe

March 10, 2016

Medicines for Europe is the new name of EGA (European Generic and Biosimilar Medicines Association) as of today. Representing the pharmaceutical companies supplying the largest share of medicines across Europe...

Sandoz proud to announce first Novartis Access treatments to Kenya

Holzkirchen, March 01, 2016

Sandoz is pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer, many of which are Sandoz medicines.

Sandoz receives positive CHMP opinion for s.c. route of administration in biosimilar Binocrit’s® nephrology indication

Holzkirchen, February 29, 2016

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.

Sandoz teams up with World Child Cancer to "even the odds" for children worldwide

Holzkirchen, February 15, 2016

Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.

Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer’s biosimilar infliximab in EEA

Holzkirchen, February 12, 2016

Sandoz, a Novartis company and a global leader in biosimilars, announced today that it has acquired from Pfizer the rights for the development and commercialization of PF-06438179 (biosimilar infliximab) in the...

Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

Holzkirchen, February 11, 2016

Sandoz, the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for its biosimilar to Amgen’s EU-licensed Neulasta®* (pegfilgrastim).

Sandoz’s Carol Lynch elected as chair of EGA’s European biosimilars group

Holzkirchen, February 10, 2016

Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).

Novartis Annual Results 2015

Basel, January 27, 2016

Novartis delivered strong sales growth and core margin expansion in 2015; announces plans to accelerate growth at Alcon, streamline Group operations.

Sandoz licenses its biosimilar rituximab to Kyowa Hakko Kirin in Japan

Holzkirchen, January 25, 2016

Sandoz announced today that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd for the distribution and promotion of its biosimilar rituximab.

Novartis moves to address superbug threat

January 21, 2016

Sandoz, part of the Novartis group, and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges.

Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept

Holzkirchen, December 08, 2015

Sandoz is seeking approval for all indications included in the reference product’s label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis.

Phase III data shows Sandoz’ proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product

Holzkirchen, December 07, 2015

PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer.

RICHARD FRANCIS ADDRESSES BIOSIMILARS AND MARKET ACCESS IN GUANDONG, CHINA

Holzkirchen, November 20, 2015

On November 19, Richard Francis, Global Head of Sandoz, a Novartis Company presented two key regional policy recommendations at this year’s International Consultative Conference for Economic Development (ICCFED) in Guangzhou, China.

Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA

Holzkirchen, November 18, 2015

Sandoz demonstrates commitment to oncology by seeking approval for its proposed biosimilar pegfilgrastim.

Generic medicines saved US healthcare system more than USD 250 billion in 2014 alone

November 05, 2015

Generic medicines saved the US healthcare system a record USD 254 billion in 2014, according to a new report compiled by the IMS Institute for Healthcare Informatics on behalf of the US Generic Pharmaceutical Association (GPhA).

Novartis Q3 Results 2015

Basel, October 27, 2015

Novartis delivered solid performance and strong pipeline progress with major approvals and key launches.

Sandoz introduces authorized generic version of LESCOL® XL in the US

Princeton, New Jersey, October 19, 2015

Sandoz today announced the US introduction of fluvastatin sodium extended-release tablets, USP, an authorized generic version of LESCOL® XL, which is marketed by Novartis Pharmaceuticals Corporation.

Kenya is first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases

Nairobi, October 15, 2015

Today, Novartis announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer.

Sandoz is a triple winner at 2015 Global Generics & Biosimilars Awards in Madrid

Holzkirchen, October 14, 2015

Last night in Madrid, Sandoz picked-up three accolades at the Global Generics & Biosimilars Awards hosted by the Generics Bulletin including Company of the Year.

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Holzkirchen, October 02, 2015

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the FDA has accepted its Biologics License Application (BLA) for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept).

Novartis launches ‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries

New York, September 24, 2015

Novartis today announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries.

Sandoz Inaugurates BioInject – a new state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria

Schaftenau, September 17, 2015

Sandoz, the generics and biosimilars business of Novartis, today officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria

Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States

Holzkirchen, Germany, September 03, 2015

Sandoz, a Novartis company, announced today that Zarxio™ (filgrastim-sndz) is now available in the United States.

Sandoz launches generic version of Pulmicort Respules®

Princeton, New Jersey, July 28, 2015

Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP.

Sandoz launches Breathe Africa program to improve asthma diagnosis, treatment and patient outcomes in Zambia

Holzkirchen, Germany, July 24, 2015

Sandoz today announced the launch of Breathe Africa, a respiratory health program aimed at improving the diagnosis and treatment of asthma through sharing medical expertise and donating medicines.

Court ruling paves the way for launch of Sandoz’s Zarxio as first US biosimilar

Holzkirchen, Germany, July 22, 2015

The US Court of Appeals for the Federal Circuit issued a ruling on July 21 that paves the way for Sandoz to launch Zarxio (filgrastim) after September 2, as the first US biosimilar.

Novartis announces second quarter results

Basel, July 21, 2015

Novartis delivered solid performance and strong pipeline progress with major approvals and key launches.

Sandoz launches the Balans programme in Central and Eastern Europe to promote healthier living

July 09, 2015

Sandoz is launching the Balans programme in a number of Central and Eastern European countries, including Slovenia, Ukraine, Kazakhstan, Latvia, Serbia and Romania, in addition to Russia and Turkey.

Novartis introduces Declaration for Patients

June 30, 2015

The Declaration for Patients articulates what patients can expect from Novartis and its divisions.

Sandoz launches three new products in Japan

Tokyo, June 25, 2015

Sandoz has announced the Japanese market introduction of three new products including clopidogrel, tacrolimus and pitavastatin (line extension).

Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg

Basel, June 18, 2015

Sandoz, a Novartis company, today announced the US launch of GlatopaTM, the first generic version of Teva's Copaxone® (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.

Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day

Basel, June 18, 2015

Novartis gathered more than 20 of its top executives from Pharmaceuticals, Alcon, Sandoz and NIBR, to meet with approximately 100 investors and analysts at the Novartis Institutes for BioMedical Research in Boston.

Delivering health equality and sustainable access to medicines for patients in Europe and worldwide

Berlin, June 10, 2015

In his opening speech at the 21st EGA Annual Conference today, EGA President Nick Haggar said that the European generic and biosimilar industry “is successfully fulfilling its mission to be the main supplier of high-quality medicines to patients in Europe, both increasing patient access and partnering for sustainable healthcare”.

Sandoz launches generic version of INTUNIV® extended release tablets in the US

Princeton, New Jersey, June 04, 2015

Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.

Sandoz Poland celebrates the opening of a new packaging plant in Stryków

Stryków, May 07, 2015

Sandoz, the generic Division of Novartis is announcing today the opening of the Sandoz Packaging Centre in Stryków – a project valued at 171 million PLN.

Novartis Q1 Results 2015

Basel, April 23, 2015

Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1; now with a more focused portfolio

Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg

Holzkirchen, Germany, April 16, 2015

Sandoz, a Novartis company, today announced the US approval of GlatopaTM, the first generic version of Teva’s Copaxone® (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.

Innovative respiratory inhaler Airflusal® Forspiro® receives Alufoil Trophy 2015

April 16, 2015

AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category.

Sandoz launches authorized generic version of EXFORGE® in the US

Princeton, New Jersey, March 31, 2015

Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

Holzkirchen, March 11, 2015

Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz

Holzkirchen, March 06, 2015

Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio™ (filgrastim-sndz) for all indications included in the reference product’s label.

Novartis announces completion of transactions with GSK

Basel, March 02, 2015

Novartis announced today that it has completed a series of transactions with GlaxoSmithKline plc (GSK).

Sandoz announces training program for midwives in Ethiopia, to reduce maternal and newborn mortality

Holzkirchen, Germany, March 02, 2015

Sandoz today announced the launch of a new program, New Life & New Hope, to improve maternal and child health and reduce mortality associated with childbirth.

On World Cancer Day, Sandoz highlights global problem of child cancer

February 04, 2015

Today is World Cancer Day and this year, under the theme ‘Not beyond us,’ Sandoz highlights the global burden of child cancer and the solutions that do exist.

Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses

Basel, January 27, 2015

Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014

Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee

Holzkirchen, January 07, 2015

Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its biosimilar filgrastim in the US.

Sandoz launches authorized generic version of Vivelle-Dot®

Princeton, New Jersey, December 22, 2014

Sandoz today announced the US market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot®, which is marketed by Novartis Pharmaceuticals Corporation.

Sandoz Brazil launches Tadalafil, first generic version of Cialis® to treat erectile dysfunction

Sao Paulo, December 18, 2014

Sandoz, the generics pharmaceutical division of Novartis, announces today that it is launching Tadalafil, a generic version of Cialis®, indicated to treat patients with erectile dysfunction.

Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®

Holzkirchen, December 08, 2014

Sandoz, a Novartis company, announced today Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN®

Sandoz receives approvals in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, November 19, 2014

Sandoz announces today that the pharmaceutical regulatory authorities in Ireland and the Czech Republic have granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz launches ready-to-use oral formulation of ACC® cough medicine in Ukraine

Kiev, November 12, 2014

Sandoz, the generic pharmaceutical division of Novartis, today announces the launch in Ukraine of a new ready-to-use oral formulation of ACC® cough medicine.

Sandoz launches first generic version of cyclophosphamide injection, USP

Princeton, November 10, 2014

Sandoz today announced the US market introduction of cyclophosphamide injection, USP.

Sandoz receives approvals in Baltics for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, November 04, 2014

Sandoz announces today that the pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania have all granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

RAND projects $44.2 billion reduction in U.S. spend on biologics over the next decade from introduction of biosimilars

November 03, 2014

Today the RAND Corporation projected that the introduction of biosimilar drugs in the US will reduce direct spending on biologics by USD 44.2 billion from 2014 to 2024.

EGA and EBG welcome a new milestone in the EU Biosimilars medicines regulatory framework

Brussels, October 30, 2014

The EGA and the European Biosimilars Group (EBG), a sector group of the EGA, congratulate the EMA and its Committee for Medicinal Products for Human Use (CHMP) and Biosimilar Medicines Working Party (BMWP) for adopting its revised overarching guideline on biosimilar medicines.

Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter

Basel, October 28, 2014

Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company."

Following commitment to United Nations’ Every Newborn Action Plan, Sandoz supplies life-saving antibiotic to combat child mortality

Holzkirchen, October 23, 2014

Sandoz delivers 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to UN and joins UN Pneumonia Innovations Team.

Sandoz' Mark McCamish discusses US Biosimilars landscape on Biocentury TV

October 14, 2014

Yesterday, Dr. Mark McCamish, Head Global Biopharmaceutical Development at Sandoz discussed the key issues around biosimilars in the US on "BioCentury This Week".

Sandoz wins Generics Bulletin 'Biosimilars Initiative of the Year' award

Holzkirchen, October 13, 2014

Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.

Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, October 09, 2014

Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

US celebrates 30 years of rapid generics growth

October 01, 2014

30 years ago, when President Ronald Reagan signed the legislation that would lay the basis for today’s US generics industry, even the law’s biggest fans never guessed quite how successful it would be.

Sandoz contributes to fighting the number one cause of death globally

September 29, 2014

Cardiovascular disease (CVD) is a global burden accounting for 17.3 million deaths a year

Sandoz launches KERYDIN TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.

Princeton, New Jersey, September 23, 2014

Sandoz, through its branded dermatology business, PharmaDerm, today announced the US launch of KERYDIN TM (tavaborole) topical solution, 5%, developed by Anacor Pharmaceuticals, Inc.

Generic medicines saved US healthcare system nearly USD 240 billion in 2013

September 18, 2014

The use of generic medicines saved US patients and payors a total of USD 239 billion in 2013 – an increase of 14% over 2012 and more than in any previous year.

Sandoz Regional BioCamp winner finishes among top three in Basel

September 02, 2014

Janko Ignjatovic of Serbia has been selected as one of three individual winners of the Novartis International BioCamp held in Basel last week. Mr. Ignjatovic, who studies pharmacy at the University of Belgrade, came to the event through the Regional BioCamp, which took place in June and was organized by Lek, a Sandoz company.

Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia

August 29, 2014

Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia.

Sandoz Brazil introduces a new option for oncology patients

São Paulo, August 26, 2014

Sandoz, the generic pharmaceutical division of Novartis, today announces the market introduction in Brazil of the first generic version of oncology medicine bortezomibe.

Sandoz receives first approval in Latin America for innovative respiratory inhaler Airflusal® Forspiro®

Holzkirchen, August 20, 2014

Sandoz announces today that the Mexican Health Authority (COFEPRIS) has granted Sandoz marketing authorization for Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz Germany launches innovative new topical therapy for erectile dysfunction, a leading urological disorder

Holzkirchen, August 18, 2014

Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Germany of Vitaros®, an innovative new topical therapy for erectile dysfunction (ED), one of the leading urological disorders in Europe and worldwide. Earlier this month, Sandoz launched Vitaros in Sweden.

Sandoz Sweden launches innovative new topical therapy for erectile dysfunction, a leading urological disorder

Holzkirchen, August 04, 2014

Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Sweden of Vitaros®, an innovative new topical therapy for erectile dysfunction (ED), one of the leading urological disorders in Europe and worldwide.

FDA accepts Sandoz application for biosimilar filgrastim

Holzkirchen, July 24, 2014

Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application for filgrastim.

Sandoz obtains rights in US to commercialize KERYDINTM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.

Princeton, New Jersey, July 21, 2014

Sandoz today announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize Anacor’s drug KERYDINTM (tavaborole) topical solution.

Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook

July 17, 2014

strong innovation momentum in second quarter, while reconfirming full year outlook

Sandoz launches authorized generic version of TOBI®

July 14, 2014

Sandoz today announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation 1.

Sandoz's Joerg Windisch Reelected as Chair of EGA’s European Biosimilars Group

July 09, 2014

Today, Sandoz announced that the European Generic medicines Agency (EGA) has reelected Dr. Joerg Windisch, Chief Science Officer at Sandoz, as chair of its European Biosimilars Group (EBG).

Sandoz brings together key French stakeholders to discuss biosimilars

July 08, 2014

Sandoz, the global leader in biosimilars, recently hosted an event in Paris for key stakeholders to discuss strategic issues impacting biosimilars and help them better understand their vital role in the success of these important therapies in France.

Sandoz launches authorized generic version of Diovan® in the US

July 08, 2014

Sandoz today announced the US introduction of an authorized generic version of Diovan® (valsartan) tablets for the treatment of high blood pressure (HBP).

Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide

Holzkirchen, June 30, 2014

Sandoz today announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation, as part of the United Nations’ new Every Newborn Action Plan.

Sandoz launches Airflusal® Forspiro® in Sweden, further driving patient access to innovative new respiratory inhaler

Holzkirchen, June 23, 2014

Sandoz today announced the launch in Sweden of Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz launches three new products in Japan, including authorized generics of valsartan and zoledronic acid

Tokyo, June 20, 2014

Sandoz announces today the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan® Tablets, zoledronic acid, a generic version of Novartis’ Zometa® for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent® Tablets LD.

GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case

Holzkirchen, June 16, 2014

Pharmaceutical company GlaxoSmithKline has withdrawn its application for a preliminary injunction on German marketing and distribution of Sandoz’s innovative and cost-effective respiratory inhaler, AirFluSal® Forspiro®, shortly before the Cologne Court of Appeals was due to rule in the case.

Sandoz launches generic version of key anti-depressant Cipralex® in several European countries

Holzkirchen, June 04, 2014

Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.

Sandoz enhances strategic relationship with Upsher-Smith through marketing agreement for potassium chloride products

Princeton, New Jersey, June 03, 2014

Sandoz today announced an agreement with Upsher-Smith to obtain exclusive US distribution rights for its branded potassium chloride line of products, Klor-Con®, and market them under the Sandoz name, enhancing its strategic relationship.

Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market

Levallois-Perret, June 02, 2014

Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, the first generic version of leading respiratory therapy Nasonex®. Mometasone Sandoz® is indicated for the treatment of conditions including allergic rhinitis.

Sandoz associates join Novartis Community Partnership Day 2014

May 15, 2014

More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day

Sandoz launches AirFluSal® Forspiro® in South Korea

Seoul, May 14, 2014

Sandoz Korea announces that it is launching today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Court supports access to Sandoz’s innovative respiratory device in Norway

May 08, 2014

We are pleased that a court in Norway has denied GSK’s request to restrict access to Sandoz’s AirFluSal® Forspiro® in Norway.

More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day

Basel, May 08, 2014

Today Novartis associates across 55 countries are engaging in local volunteer efforts to support their communities in celebration of the company's annual Community Partnership Day (CPD).

Sandoz launches generic version of Differin® Gel, 0.3%

Princeton, New Jersey, April 28, 2014

Sandoz today announced the US market introduction of its adapalene 0.3% gel, a generic version of Galderma Laboratories’ Differin® Gel, 0.3%.

SANDOZ ACHIEVES IMPORTANT MILESTONES ON PHASE III TRIALS FOR KEY BIOSIMILARS PROGRAMS

April 28, 2014

Sandoz continues to advance its industry-leading biosimilars pipeline that currently has six molecules in the Phase III clinical trial/filing prep phase.

Novartis announces Q1 2014 results

Basel, April 24, 2014

Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

Basel, April 22, 2014

Novartis announced today that it has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio.

Sandoz demonstrates innovation strength at “Long Night of Research“

April 11, 2014

On April 4, Sandoz participated for the first time in the “Long Night of Research” in Innsbruck, Austria.

Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz

Basel, April 09, 2014

New leaders to continue to build global scale and innovation power in two of the leading Novartis businesses

Sandoz launches AirFluSal® Forspiro® in Norway

Holzkirchen, April 02, 2014

Sandoz announces today that it is launching in Norway AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz launches first generic version of Taclonex® Ointment

Princeton, New Jersey, April 01, 2014

Sandoz today announced the US market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex® Ointment.

Sandoz launches generic version of PREVPAC® in the US

Princeton, New Jersey, March 27, 2014

Sandoz today announced the US launch of lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP, a generic version of PREVPAC®

Vas Narasimhan to lead Sandoz’ biosimilars business

Munich,Germany, March 27, 2014

Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014

Sandoz receives approval for biosimilar filgrastim in Japan

Munich,Germany, March 24, 2014

Sandoz announced today that Sandoz Japan has received marketing authorization approval for its biosimilar filgrastim (Kyowa Hakko Kirin’s GRAN®).

Tuberculosis remains a global health challenge; Sandoz continues commitment to fighting the disease

March 24, 2014

Today is World Tuberculosis Day. Despite great progress made in the fight to eradicate Tuberculosis (TB), the disease remains a global killer and disproportionately affects the world’s poor. Sandoz, a leading provider of high-quality, affordable generic medicines, has the opportunity to significantly contribute to the fight against TB.

South Korea approves AirFluSal® Forspiro®

Munich,Germany, February 28, 2014

Sandoz announced today it has received South Korean marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.

Jeff George speaks to Generics Bulletin about emerging markets

Holzkirchen, February 25, 2014

An increase of a tenth to US$2.53 billion in turnover from emerging growth markets enabled Sandoz to raise its total turnover by 5% to US$9.16 billion last year, Generics Bulletin reported in a recent article.

Belgium Approves Sandoz’S Airfusal® Forspiro®

Holzkirchen, Germany, February 12, 2014

Sandoz announced it has received marketing authorization in Belgium for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Norway approves Sandoz’s AirFluSal® Forspiro®

Holzkirchen, Germany, February 10, 2014

Sandoz announced today it has received Norwegian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Sandoz launches the first generic version of Hectorol®

Princeton, New Jersey, February 05, 2014

Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme's Hectorol®.

Bulgaria approves Sandoz’s AirFluSal® Forspiro®

Holzkirchen, Germany, February 04, 2014

Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD

Romania approves Sandoz’s AirFluSal® Forspiro®

Holzkirchen, Germany, January 29, 2014

Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Novartis announces Q4/Full Year 2013 results

Basel, January 29, 2014

Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects

Sandoz launches AirFluSal ® Forspiro® in Denmark

Copenhagen, January 20, 2014

Sandoz announces that it is launching in Denmark today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Hungary approves Sandoz’s AirFluSal® Forspiro®

Holzkirchen, Germany, January 16, 2014

Sandoz announced it has received marketing authorization in Hungary for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Sweden approves Sandoz’s AirFluSal® Forspiro®

Holzkirchen, Germany,, January 14, 2014

Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Germany approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 13, 2014

Sandoz announced today it has received German marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

Sandoz receives first approval for AirFluSal® Forspiro®

Munich, December 18, 2013

Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval follows the completion of EU decentralized procedures (DCP) for eight EU countries, including Denmark.

Sandoz begins Phase III clinical trial for biosimilar adalimumab

December 18, 2013

Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie’s HUMIRA®) – the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn’s disease. This is Sandoz’s eighth Phase III trial initiation across six compounds.

Sandoz B.V. and Novartis Confirm Receipt of a Decision from the European Commission

December 10, 2013

Sandoz B.V., a subsidiary of Novartis, and Novartis confirm that they received the European Commission’s decision that a 2005 agreement between Sandoz subsidiaries in the Netherlands and Janssen-Cilag related to the co-promotion of Fentanyl violated competition law.

Novartis Africa Day highlights company’s efforts to expand access to healthcare

Basel, December 05, 2013

Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company’s Malaria Initiative.

Sandoz launches an authorized generic version of Solaraze® Gel

Princeton, New Jersey, November 21, 2013

Sandoz today announced the US launch of diclofenac 3% gel, an authorized generic version of PharmaDerm’s Solaraze® Gel.

Sandoz Recognizes World Diabetes Day

November 14, 2013

November 14 is World Diabetes Day, held each year by the International Diabetes Federation (IDF) to raise global awareness about the fight against diabetes mellitus. World Diabetes Day was founded in 1991 by the IDF and World Health Organization in response to the alarming rise of diabetes around the world.

Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety

Basel, Switzerland, October 30, 2013

Novartis announced today it has filed a Citizen Petition with the US Food and Drug Administration (FDA), urging the Agency to require that a biosimilar share the same INN as the reference product.

Sandoz Applauds Governor Brown For Vetoing California Biosimilars Bill

California, USA, October 15, 2013

Sandoz welcomes California Governor Jerry Brown’s veto of legislation that threatened to restrict patient access to biosimilars – high-quality follow-on versions of existing biologic medicines to treat complex disorders including cancer and autoimmune diseases

Sandoz recognizes International Day of Rural Women

October 15, 2013

An interview with three Sandoz leaders in Africa on the current health challenges facing rural women

Sandoz’s Nick Haggar named new EGA president

Holzkirchen, Germany, October 02, 2013

The European Generic medicines Association (EGA) has named Sandoz’s Nick Haggar as the new incoming president of the European generic medicines industry body.

Sandoz launches an authorized generic of key oncology product VIDAZA®

September 23, 2013

Princeton, New Jersey, September 23, 2013 – Sandoz today announced the US launch of azacitidine for injection, an authorized generic version of Celgene’s VIDAZA®.

Sandoz launches SurePalTM – Simple and Secure Device Innovation for Patients Using Human Growth Hormone (hGH)

Holzkirchen, September 23, 2013

Sandoz announced today the launch of SurePal™, a new delivery device to optimize the simplicity and security of administering Omnitrope® human growth hormone for patients, their physicians and care givers. SurePal has been CE marked in accordance with European Union (EU) laws on medical devices. The device is now available for patients in the United Kingdom and will be launched globally.

Sandoz supports tuberculosis awareness film in cooperation with Indian Ministry of Health

Mumbai,India, September 12, 2013

Partnerships with local health authorities support community engagement programs to raise awareness, provide preventive solutions and counter many myths surrounding tuberculosis.

Sandoz Canada launches Salinex ProTectTM

Boucherville, QC, August 27, 2013

Sandoz Canada announced today the launch in Canada of Salinex ProTectTM.

Sandoz launches Nexmezol, treatment for digestive disorders, in South Africa

Johannesburg, August 21, 2013

Sandoz, the generic pharmaceuticals division of Novartis, has launched Nexmezol. Nexmezol is the first generic esomeprazole in South Africa.

Sandoz launches an authorized generic version of temozolomide capsules

Princeton, New Jersey, August 13, 2013

Sandoz today announced the US launch of temozolomide capsules.

Announcing re-launch of Sandoz-Biosimilars.com

August 08, 2013

Sandoz is excited to announce the re-launch of our biosimilars website, Sandoz-Biosimilars.com

US FEDERAL CIRCUIT COURT OF APPEALS FINDS SANDOZ’S GENERIC COPAXONE® DOES NOT INFRINGE TEVA’S 2015 PATENT

Princeton, New Jersey, July 26, 2013

Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents asserted against the company by Teva Pharmaceuticals in litigation concerning a generic version of Copaxone® – one of the leading products marketed for the treatment of multiple sclerosis.

CHMP Positive Opinion on Methylphenidate

Holzkirchen, Germany, July 26, 2013

CHMP announced today a positive opinion on the risk-benefit ratio of Methylphenidate Sandoz and Methylphenidate Hexal, after completion of a respective arbitration procedure on July 25, 2013.

NEW EPISODE OF SANDOZ TV AVAILABLE

July 25, 2013

Sandoz has just launched its fourteenth episode of Sandoz TV.

NEW EPISODE OF SANDOZ TV AVAILABLE

July 25, 2013

Sandoz has just launched its fourteenth episode of Sandoz TV.

Sandoz’s Nick Haggar speaks to Generics Bulletin

Holzkirchen, Germany, July 22, 2013

“Seeking short-term savings and imposing ever more demanding rules is endangering supplies of affordable generics in Europe,” said Nick Haggar, Sandoz Head of Western Europe, Middle East and Africa, in a recent interview with Generics Bulletin’s Aidan Fry.

SANDOZ’S AMEET MALLIK SPEAKS TO GENERICS BULLETIN

Holzkirchen, Germany, July 22, 2013

Anticipated approvals of biosimilar infliximabs in the EU will usher in a new era for biosimilars, according to a recent Generics Bulletin article featuring Sandoz Global Head of Biopharmaceuticals and Oncology Injectables, Ameet Mallik.

ZARZIO® OVERTAKES NEUPOGEN® AND GRANOCYTE® TO BECOME MOST PRESCRIBED DAILY G-CSF IN EUROPE

Holzkirchen, Germany, July 22, 2013

Sandoz, the global leader in biosimilars, is pleased that Zarzio® (filgrastim) has become the first biosimilar to overtake both its reference product (Amgen’s Neupogen®) and European market leader (Chugai’s Granocyte®) and is now the most prescribed daily G-CSF in Europe and the #1 biosimilar daily G-CSF globally.

Sandoz’s Helmut Fabry speaks to Generics Bulletin

Holzkirchen, Germany, July 22, 2013

In this recent Generics Bulletin article, Helmut Fabry provides an insider look at the German Generics business and explains why Sandoz is pursuing a ‘pockets of growth’ strategy.

Novartis announces its second quarter and half year results for 2013 today.

Basel, July 17, 2013

Novartis delivered growth across all divisions in second quarter (cc); raises guidance for full year 2013.

Sandoz launches first generic version of METROGEL® 1% in the US

Princeton, New Jersey, July 02, 2013

Sandoz today announced the US launch of metronidazole 1% topical gel, the first generic version of METROGEL® 1%.

Sandoz launches Phase III clinical trial for biosimilar etanercept

Holzkirchen,Germany, June 24, 2013

Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen’s Enbrel®).

Sandoz launches generic version of BENET® Tablets / ACTONEL® Tab in Japan

Tokyo,Japan, June 21, 2013

Sandoz today announces the National Health Insurance price listing and launch in Japan of sodium risedronate tablets 2.5mg/17.5 mg [Sandoz], the generic version of BENET® Tablets / ACTONEL® Tab.

Sandoz responds to EMA Draft Revision of Biosimilar Development Guidelines

June 19, 2013

Sandoz is pleased that the European Medicines Agency (EMA) has issued a draft revised guideline on non-clinical and clinical issues in biosimilar product development.

FACTS & FIGURES 2012 NOW AVAILABLE

Holzkirchen, June 07, 2013

Find out more about Sandoz’s 2012 performance, key achievements, main therapeutic areas, top 10 worldwide products, locations around the globe as well as our global standing in biosimilars, injectables, inhalables, ophthalmics and dermatology.

Sandoz responds to FDA warning letter

Holzkirchen, June 04, 2013

Sandoz and Novartis announced today that the U.S. Food and Drug Administration (FDA) issued a Warning Letter concerning the company’s Unterach, Austria site.

Sandoz launches first generic version of ATACAND®

Princeton, New Jersey, May 22, 2013

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of candesartan cilexetil tablets, the first generic version of ATACAND®.

Novartis wins GBCHealth Business Action on Health Award for social ventures initiative

Basel, Switzerland, May 17, 2013

Novartis is pleased to announce that GBCHealth, a coalition of more than 230 private sector companies working to improve global health, has awarded the company's Arogya Parivar program the Business Action on Health Award for Application of Core Competence. Arogya Parivar is a sustainable business model that makes affordable, high-quality medicines accessible to underserved millions in India. The program also expands access to health education and consultations in remote villages.

New episode of Sandoz TV available

May 13, 2013

Sandoz has just launched its fourteenth episode of Sandoz TV.

Celebrating Novartis’ 17th Community Partnership Day

Holzkirchen, Germany, April 25, 2013

On April 25th we celebrate Novartis’ 17th annual Community Partnership Day. This company-wide initiative, which encourages all associates to engage in volunteering for charitable causes, is another example of our long-standing commitment to being a responsible company.

Sandoz Files for Marketing Authorization of Biosimilar Filgrastim in Japan

Tokyo,Japan, April 25, 2013

Sandoz today announced that it has filed an application with the Japanese health authority (PMDA) for marketing authorization of EP2006, a biosimilar version of recombinant human granulocyte colony stimulating factor (G-CSF).

Novartis announces Q1 2013 results

Basel, April 24, 2013

Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth

Sandoz’ Mark McCamish ranked 12th most influential person in antibody industry

Holzkirchen, Germany, April 18, 2013

The European Antibody Congress 2013 has named Sandoz’ Mark McCamish, Head Global Biopharmaceutical Development, as one of the top 50 global antibody industry influencers of today.

Sandoz strengthens oral contraceptive portfolio by launching generic versions of Ortho Cyclen® and Ortho Tri-Cyclen®

Princeton, New Jersey, March 19, 2013

Sandoz today announced the US Food and Drug Administration (FDA) approvals and US launches of Estarylla™ (norgestimate and ethinyl estradiol tablets) and Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets), generic equivalents of the oral contraceptives Ortho Cyclen® and Ortho Tri-Cyclen®.

Sandoz expands Kundl site sterile production

Kundl, Austria, March 11, 2013

Sandoz officially opened its new facilities in Kundl, Austria, thereby expanding the production of sterile penicillins at the site significantly and creating 30 new jobs.

Sandoz launches an authorized generic version of argatroban injection (aqueous solution for intravenous infusion)

Princeton, New Jersey, February 19, 2013

Sandoz today announced the US launch of an authorized generic version of Eagle Pharmaceuticals’ ready-to-use argatroban injection 50 mg/50mL, aqueous solution (1 mg/mL).

Sandoz launches first generic version of Cleocin Phosphate® in Dextrose 5%

Princeton, New Jersey, February 06, 2013

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of clindamycin in 5% dextrose in minibag form, the first generic version of Cleocin Phosphate® in Dextrose 5%.

Sandoz and Novartis confirm receipt of EU Statement of Objection

Holzkirchen, January 31, 2013

Sandoz B.V., a subsidiary of Novartis, and Novartis have received on Jan. 31st a Statement of Objections from the European Commission in relation to the Commission's Fentanyl investigation in which formal proceedings were initiated in October 2011.

NEW EPISODE OF SANDOZ TV AVAILABLE

January 25, 2013

Sandoz has just launched its fourteenth episode of Sandoz TV.

NOVARTIS ANNOUNCES Q4/FULL YEAR 2012 RESULTS

Basel, January 23, 2013

Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013.

Sandoz launches first generic version of DUETACT®

Princeton, New Jersey, January 11, 2013

Sandoz today announced the US market introduction of its first-to-file pioglitazone hydrochloride and glimepiride tablets, the first generic version of Takeda Pharmaceuticals’ DUETACT®.

The first Bioequivalence Center in East Africa is launched with support from Sandoz

Holzkirchen, Germany, December 05, 2012

The first regional Bioequivalence Center in East Africa, based in Addis Ababa, was officially inaugurated on November 14th by His Excellency Tadesse Haile, State Minister of the Ministry of Industry of the Federal Republic of Ethiopia. Important stakeholders from Ethiopia, Kenya, Tanzania, Uganda including regulators, university professors, pharmaceutical professional organizations, WHO officials, and diplomats attended the ceremony.

Sandoz begins phase III studies in the United States for biosimilar epoetin alfa

Holzkirchen, Germany, October 25, 2012

Sandoz, the global leader in biosimilars, has started patient enrolment in a late stage clinical trial in the United States for its biosimilar epoetin alfa.

Novartis announces Q3 2012 results

Basel, October 25, 2012

Recently launched products support Novartis sales in third quarter, offsetting patent expiry; Pharmaceuticals well-positioned with further pipeline progress

Sandoz strengthens leadership in generic dermatology with launch of generic version of TOPICORT® 0.25% Ointment

Princeton, New Jersey, October 10, 2012

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of desoximetasone ointment USP, 0.25%, a generic equivalent of leading dermatology medicine TOPICORT® 0.25% Ointment.

Novartis Group maximizes patient access and choice with launch of Sandoz authorized generic Diovan HCT® in the US

New York, September 21, 2012

Sandoz, the generics division of Novartis, today announced the US introduction of an authorized generic version of Diovan HCT® (valsartan and hydrochlorothiazide) tablets for the treatment of high blood pressure (HBP).

Sandoz strengthens US respiratory portfolio with launch of generic version of SINGULAIR®

Princeton, New Jersey, August 06, 2012

Princeton, New Jersey, August 6, 2012 – Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of montelukast sodium, a generic equivalent of leading respiratory medicine SINGULAIR®.

Sandoz launches first-to-file calcipotriene cream, the first generic version of Dovonex®

Princeton, New Jersey, August 03, 2012

Sandoz today announced the introduction of its first-to-file calcipotriene cream, the first generic version of LEO Pharma Inc.’s Dovonex® Cream, 0.005% in the US.

Sandoz completes acquisition of Fougera Pharmaceuticals, positioning Sandoz as #1 in generic dermatology globally

Holzkirchen, July 23, 2012

Sandoz has completed its USD 1.525 billion acquisition of specialty US dermatology company Fougera Pharmaceuticals on a cash and debt free basis.

Novartis announces Q2 2012 results

Basel, July 19, 2012

Novartis second quarter results enhance future growth prospects with eight significant regulatory milestones; on track to deliver 2012 outlook.

New study shows biosimilars can save healthcare systems of eight EU countries up to EUR 33 billion by 2020

Holzkirchen, Germany, May 18, 2012

Latest study by IGES institute shows biosimilars offer a solution for healthcare systems facing increasing biologics costs.

New episode of Sandoz TV available

May 15, 2012

Sandoz has just launched its fourteenth episode of Sandoz TV.

Sandoz testimony at FDA hearing on biosimilars will emphasize need for consistent regulatory standards across all biologics

Holzkirchen, Germany, May 09, 2012

Sandoz announced today that Dr. Mark McCamish, Head of Global Biopharmaceutical Development, will present on behalf of the Novartis Group of companies (Novartis) at the May 11 Food and Drug Administration (FDA) public hearing on draft guidances related to the development of biosimilar products.

Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US

Basel, Switzerland, May 02, 2012

Definitive agreement to acquire Fougera Pharmaceuticals for USD 1.525 billion in an all-cash transaction

Novartis announces Q1 2012 results

Basel, April 24, 2012

Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges

Novartis announces Q4/Full Year 2011 results

Basel, January 25, 2012

Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011

NOVARTIS ANNOUNCES Q2 2011 RESULTS

Basel, July 19, 2011

Novartis delivers strong financial results and four major approvals in second quarter of 2011.

NOVARTIS ANNOUNCES Q1 2011 RESULTS

Basel, April 19, 2011

Novartis makes a strong start for the year.

PAGE:   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20